Mirum Pharmaceuticals Inc (MIRM)
25.81
+0.51
(+2.02%)
USD |
NASDAQ |
May 21, 16:00
25.81
0.00 (0.00%)
After-Hours: 16:24
Mirum Pharmaceuticals Enterprise Value: 1.196B for May 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 20, 2024 | 1.196B |
| May 17, 2024 | 1.138B |
| May 16, 2024 | 1.171B |
| May 15, 2024 | 1.182B |
| May 14, 2024 | 1.173B |
| May 13, 2024 | 1.172B |
| May 10, 2024 | 1.171B |
| May 09, 2024 | 1.221B |
| May 08, 2024 | 1.184B |
| May 07, 2024 | 1.225B |
| May 06, 2024 | 1.248B |
| May 03, 2024 | 1.222B |
| May 02, 2024 | 1.210B |
| May 01, 2024 | 1.216B |
| April 30, 2024 | 1.187B |
| April 29, 2024 | 1.185B |
| April 26, 2024 | 1.157B |
| April 25, 2024 | 1.158B |
| April 24, 2024 | 1.136B |
| April 23, 2024 | 1.155B |
| April 22, 2024 | 1.143B |
| April 19, 2024 | 1.126B |
| April 18, 2024 | 1.115B |
| April 17, 2024 | 1.128B |
| April 16, 2024 | 1.135B |
| Date | Value |
|---|---|
| April 15, 2024 | 1.131B |
| April 12, 2024 | 1.162B |
| April 11, 2024 | 1.221B |
| April 10, 2024 | 1.212B |
| April 09, 2024 | 1.237B |
| April 08, 2024 | 1.224B |
| April 05, 2024 | 1.240B |
| April 04, 2024 | 1.196B |
| April 03, 2024 | 1.168B |
| April 02, 2024 | 1.190B |
| April 01, 2024 | 1.202B |
| March 31, 2024 | 1.186B |
| March 28, 2024 | 1.201B |
| March 27, 2024 | 1.201B |
| March 26, 2024 | 1.191B |
| March 25, 2024 | 1.249B |
| March 22, 2024 | 1.248B |
| March 21, 2024 | 1.244B |
| March 20, 2024 | 1.289B |
| March 19, 2024 | 1.290B |
| March 18, 2024 | 1.241B |
| March 15, 2024 | 1.278B |
| March 14, 2024 | 1.344B |
| March 13, 2024 | 1.325B |
| March 12, 2024 | 1.312B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
30.99M
Minimum
Nov 20 2019
1.628B
Maximum
Dec 15 2023
580.49M
Average
438.45M
Median
Nov 27 2020
Enterprise Value Benchmarks
| Vanda Pharmaceuticals Inc | -87.44M |
| Sarepta Therapeutics Inc | 12.22B |
| Puma Biotechnology Inc | 203.66M |
| Reneo Pharmaceuticals Inc | -19.34M |
| Tharimmune Inc | -3.994M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -25.28M |
| Revenue (Quarterly) | 69.22M |
| Total Expenses (Quarterly) | 95.69M |
| EPS Diluted (Quarterly) | -0.54 |
| Gross Profit Margin (Quarterly) | 74.24% |
| Profit Margin (Quarterly) | -36.52% |
| Earnings Yield | -14.57% |
| Normalized Earnings Yield | -14.57 |